Increased glucose metabolism in the adult hypertrophied heart is not harmful and can be beneficial when providing sufficient fuel for oxidative metabolism.
In cardiac hypertrophy, increased reliance on glucose is not inherently harmful and may be beneficial if it supports oxidative metabolism, suggesting metabolic therapies should target oxidative capacity.
The most notable change in the metabolic profile of hypertrophied hearts is an increased reliance on glucose with an overall reduced oxidative metabolism, i.e. a reappearance of the foetal metabolic pattern. In animal models, this change is attributed to the down-regulation of the transcriptional cascades promoting gene expression for fatty acid oxidation and mitochondrial oxidative phosphorylation in adult hearts. Impaired myocardial energetics in cardiac hypertrophy also triggers AMP-activated protein kinase (AMPK), leading to increased glucose uptake and glycolysis. Aside from increased reliance on glucose as an energy source, changes in other glucose metabolism pathways, e.g. the pentose phosphate pathway, the glucosamine biosynthesis pathway, and anaplerosis, are also noted in the hypertrophied hearts. Studies using transgenic mouse models and pharmacological compounds to mimic or counter the switch of substrate preference in cardiac hypertrophy have demonstrated that increased glucose metabolism in adult heart is not harmful and can be beneficial when it provides sufficient fuel for oxidative metabolism. However, improvement in the oxidative capacity and efficiency rather than the selection of the substrate is likely the ultimate goal for metabolic therapies.
Kolwicz et al. (Mon,) conducted a review in Cardiac hypertrophy. Metabolic therapies targeting glucose metabolism was evaluated. Increased glucose metabolism in the adult hypertrophied heart is not harmful and can be beneficial when providing sufficient fuel for oxidative metabolism.